Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Liothyronine
Drug ID BADD_D01296
Description Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine.[T457] The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.[L5578]
Indications and Usage Liothyronine is officially approved for the following indications: - Replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. - As an adjunct therapy to surgery and radioiodine in the management of thyroid cancer. - As a diagnostic agent in suppression tests for mild hyperthyroidism or thyroid gland autonomy.[FDA label] In general terms, exogenous liothyronine is used to replace insufficient hormonal production and restore T3 plasma levels.[T457] The lack of liothyronine can be presented as a pale and puffy face, coarse, brittle hair, dry skin, croaky voice and constipation as well as irregular periods, drowsiness, and lethargy.[T457] Liothyronine should never be used in the suppression of benign nodules and nontoxic diffuse goiter in iodine-sufficient patients nor in the treatment of hyperthyroidism during the recovery phase of subacute thyroiditis.[FDA label]
Marketing Status approved; vet_approved
ATC Code H03AA02
DrugBank ID DB00279
KEGG ID D08128
MeSH ID D014284
PubChem ID 5920
TTD Drug ID D0S6JG
NDC Product Code 81955-0009
UNII 06LU7C9H1V
Synonyms Triiodothyronine | T3 Thyroid Hormone | Thyroid Hormone, T3 | Liothyronine | 3,3',5-Triiodothyronine | Liothyronine Sodium | Cytomel
Chemical Information
Molecular Formula C15H12I3NO4
CAS Registry Number 15785-49-6
SMILES C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)O)N)I)I)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Headache17.14.01.0010.003090%
Hepatic neoplasm09.04.03.001; 16.07.03.0010.000249%Not Available
Hypersensitivity10.01.03.0030.000548%
Hypertension24.08.02.0010.000548%
Hyperthyroidism14.11.01.011; 05.02.02.0010.001969%
Hypotension24.06.03.002--
Hypothyroidism14.11.01.012; 05.02.03.0010.002368%
Insomnia19.02.01.002; 17.15.03.0020.001097%
Loss of consciousness17.02.04.0040.000249%Not Available
Malaise08.01.01.0030.002492%
Migraine17.14.02.001; 24.03.05.0030.000548%Not Available
Muscle twitching15.05.03.005--Not Available
Musculoskeletal pain15.03.04.0070.000673%
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocarditis02.04.03.0010.000249%
Pain in extremity15.03.04.0100.000548%
Palpitations02.11.04.0120.002866%
Phlebitis24.12.03.004; 12.02.01.002--
Pollakiuria20.02.02.0070.000548%
Pruritus23.03.12.0010.000972%
Pulmonary embolism24.01.06.001; 22.06.02.0010.000374%Not Available
Rash23.03.13.0010.002118%Not Available
Sinus tachycardia02.03.03.0100.000249%
Skin disorder23.03.03.0070.000847%Not Available
Sluggishness08.01.01.0040.000847%Not Available
Swelling face08.01.03.100; 10.01.05.018; 23.04.01.0180.000847%Not Available
Tachycardia02.03.02.007--Not Available
Visual impairment06.02.10.0130.000548%Not Available
Peripheral swelling08.01.03.053; 02.05.04.0150.000972%Not Available
Left ventricular hypertrophy02.04.02.0140.000374%Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages